Therapeutic Evaluation of Bifidobacterium animalis subsp. lactis MH-02 as an Adjunctive Treatment in Patients with Reflux Esophagitis: A Randomized, Double-Blind, Placebo-Controlled Trial
Gan L, Wang Y, Huang S, Li Z
Published in Nutrients
Methodology
Randomized double-blind placebo-controlled trial of adjunctive Bifidobacterium animalis subsp. lactis MH-02 with standard PPI therapy in reflux esophagitis
Key Findings
Adjunctive probiotic supplementation improved GERD symptom scores and quality of life versus placebo alongside standard PPI therapy
Conclusions
Bifidobacterium animalis subsp. lactis MH-02 may be a beneficial adjunct to acid-suppressive therapy
Limitations
Single strain limits generalisability; short follow-up; single-centre design
Supplements Studied
Bifidobacterium animalis subsp. lactis MH-02 as an adjunctive treatment improved clinical symptoms in patients with reflux esophagitis.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Commercial probiotic strain manufacturer collaboration
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.